Concepedia

Author

Joseph P. Eder

Dana-Farber Cancer InstituteORCID

Also Known As

Eder, Joseph, J EDER, J Eder, J P Eder, J Paul Eder, J. Eder, J. P. Eder, J. Paul Eder, J.P. Eder, JOSEPH P. EDER

330

Publications

24.4K

Citations

55

H-Index

122

Concepts

All Affiliations

Dana-Farber Cancer InstituteYale Cancer CenterYale UniversityMerck & Co., Inc., Rahway, NJ, USA (United States)Massachusetts General Hospital
JP

About

Joseph P. Eder is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

39

79

11.3K

2

Health Sciences

15

18

786

3

Natural Sciences

2

2

71

4

Education

1

1

11

5

Law

1

1

11

Joseph P. Eder

×

130

Publications

23.1K

Citations

55

H-Index

YearCitations

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui,

New England Journal of Medicine

2015

6.1K

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Thomas Powles, Joseph P. Eder, Gregg Fine,

Nature

2014

2.4K

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

Tanguy Y. Seiwert, Barbara Burtness, Ranee Mehra,

The Lancet Oncology

2016

1.7K

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Scott Antonia, José A. López-Martín, Johanna C. Bendell,

The Lancet Oncology

2016

1.2K

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

Kei Muro, Hyun Cheol Chung, Veena Shankaran,

The Lancet Oncology

2016

1.1K

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta,

Journal of Clinical Oncology

2016

846

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

Leisha A. Emens, Cristina Cruz, Joseph P. Eder,

JAMA Oncology

2018

774

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

Ranee Mehra, Tanguy Y. Seiwert, Shilpa Gupta,

British Journal of Cancer

2018

443

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.

Karen H. Antman, Lois Ayash, Anthony Elias,

Journal of Clinical Oncology

1992

374

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

Neal Ready, Anna F. Farago, Filippo de Braud,

Journal of Thoracic Oncology

2018

373

Page 1